109 filings
Page 2 of 6
8-K/A
8mjexx nckv4ifex
1 Jun 22
Changes in Registrant's Certifying Accountant
7:01am
8-K
o3gfybkpresl2 4e
31 May 22
Other Events
8:51am
8-K
ttfhu5qg
10 May 22
Zai Lab Announces First Quarter 2022
4:10pm
8-K/A
gac08e1gmgecq
2 May 22
Changes in Registrant's Certifying Accountant
4:31pm
8-K
dluacgwp76qrvowy4e2
21 Apr 22
Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm
7:34am
8-K
47d5eepiikzausv3
1 Apr 22
Departure of Directors or Certain Officers
4:32pm
8-K
l2xiam4 g4ml8tvck
28 Mar 22
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
xw6m9h
15 Mar 22
Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer
8:31am
8-K
2z9eh 42bt1mq83
1 Mar 22
Results of Operations and Financial Condition
4:17pm
8-K
s1t2r
6 Jan 22
Zai Lab Announces NDA Acceptance of
7:44am
8-K
lycsw54rxggxte6i
22 Dec 21
Zai Lab announces promotion of Harald Reinhart M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases
4:14pm
8-K
iclhq6c
16 Dec 21
China NMPA Approves NUZYRA® as a Category 1
7:43am
8-K
d3yk5o4ooj51 ajk
3 Dec 21
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer
7:45am
8-K
rt1qto9l6lzswd2t74w
22 Nov 21
Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors
7:40am
8-K
y4pw7 uh15
9 Nov 21
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License
4:26pm
8-K
r5m5 drdea
5 Nov 21
Other Events
4:14pm
8-K
62qy4w bhf9pk7vb
20 Oct 21
ZL-1102, Zai Lab’s Internally Developed Novel Human
4:06pm
8-K
wryfaueuets18ii
19 Oct 21
Zai Lab and Entasis Therapeutics Announce Positive
9:21am
8-K
97178r4s7mu
18 Oct 21
Zai Lab Appoints Scott Morrison
7:38am
8-K
0nharzpinejr9qk9h
9 Aug 21
Zai Lab Announces Second Quarter 2021
4:06pm